Development of a neuronal scoring systemin vitro for potential hazard identification in early drug safety de-risking

被引：0
|
作者：
Kreir, Mohamed [1 ]
Putri, Dea [2 ]
Tekle, Fetene [1 ]
Van Ammel, Karel [1 ]
Lu, Hua Rong [1 ]
Teisman, Ard [1 ]
Gallacher, David J. [1 ]
机构：
[1] Janssen R&D, Beerse, Belgium
[2] Hasselt Univ, Diepenbeek, Limburg, Belgium
来源：
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS | 2023年 / 123卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
SP033
引用
收藏
页数：1
相关论文
共 18 条
  • [1] Development of a Human iPSC Cardiomyocyte-Based Scoring System for Cardiac Hazard Identification in Early Drug Safety De-risking
    Kopljar, Ivan
    Lu, Hua Rong
    Van Ammel, Karel
    Otava, Martin
    Tekle, Fetene
    Teisman, Ard
    Gallacher, David J.
    [J]. STEM CELL REPORTS, 2018, 11 (06): : 1365 - 1377
  • [2] De-Risking Drug Discovery with ADDME - Avoiding Drug Development Mistakes Early
    Tsaioun, Katya
    Jacewicz, Mary
    [J]. ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2009, 37 : 47 - 55
  • [3] Developability assessment as an early de-risking tool for biopharmaceutical development
    Zurdo, Jesus
    [J]. PHARMACEUTICAL BIOPROCESSING, 2013, 1 (01) : 29 - 50
  • [4] Target safety assessments and their role in de-risking drug discovery: NaV1.7 as an example
    Eades, Lauren
    Sadler, Claire
    Knight, Richard
    Morton, Michael
    Roberts, Ruth
    [J]. TOXICOLOGY LETTERS, 2017, 280 : S224 - S225
  • [5] Development of a new hazard scoring system in primary neuronal cell cultures for drug-induced acute neuronal toxicity identification in early drug discovery
    Kreir, Mohamed
    Putri, Dea
    Tekle, Fetene
    Pibiri, Francesca
    d'Ydewalle, Constantin
    Van Ammel, Karel
    Geys, Helena
    Teisman, Ard
    Gallacher, David J.
    Lu, Hua Rong
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective
    Etkin, Amit
    Powell, Jessica
    Savitz, Adam J.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2024,
  • [7] De-risking primary and secondary pharmacology mediated adverse effects as a path to increase likelihood of success in drug development
    Valentin, Jean-Pierre
    Atienzar, Franck
    Class, Reiner
    Delaunois, Annie
    Fleurance, Renaud
    Gerets, Helga
    Glineur, Stephanie
    Gryshkova, Vitalina
    Hall, Peter
    Hasselgren, Catrin
    Tilmant, Karen
    [J]. TOXICOLOGY LETTERS, 2017, 280 : S77 - S77
  • [8] The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development
    Heslop, Emma
    Csimma, Cristina
    Straub, Volker
    McCall, John
    Nagaraju, Kanneboyina
    Wagner, Kathryn R.
    Caizergues, Didier
    Korinthenberg, Rudolf
    Flanigan, Kevin M.
    Kaufmann, Petra
    McNeil, Elizabeth
    Mendell, Jerry
    Hesterlee, Sharon
    Wells, Dominic J.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [9] The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development
    Emma Heslop
    Cristina Csimma
    Volker Straub
    John McCall
    Kanneboyina Nagaraju
    Kathryn R Wagner
    Didier Caizergues
    Rudolf Korinthenberg
    Kevin M Flanigan
    Petra Kaufmann
    Elizabeth McNeil
    Jerry Mendell
    Sharon Hesterlee
    Dominic J Wells
    Kate Bushby
    [J]. Orphanet Journal of Rare Diseases, 10
  • [10] The TREAT-NMD Advisory Committee for Therapeutics (TACT): An innovative de-risking model to foster orphan drug development
    Wells, D.
    Heslop, E.
    Csimma, C.
    Straub, V.
    McCall, J.
    Nagaraju, K.
    Wagner, K.
    Caizergues, D.
    Korinthenberg, R.
    Flanigan, K.
    Mendell, J.
    Kelly, M.
    Kaufmann, P.
    McNeil, E.
    Robertson, A.
    Johnston, L.
    Bushby, K.
    [J]. NEUROMUSCULAR DISORDERS, 2015, 25 : S271 - S271
12